Share this article
Share this article
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ Inmagene Biopharmaceuticals ( Inmagene ), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary in San Diego. Jean-Louis Saillot, MD has joined the company as Chief Development Officer (CDO) to oversee its global product development and clinical trial activities. Inmagene U.S. is integral to our global innovation platform, said Dr. Jonathan Wang, Inmagene s Chairman and CEO. Dr. s Saillot has brought us over three decades of clinical research and development experience from multinational pharmaceutical companies, such as BMS/Celgene, Merck/Schering-Plough, and SmithKline Beecham. His experience in leading multiple successful NDAs/MMAs will greatly boost Inmagene s global drug development capabilities, and enable us to introduce well-needed medicines to the large patient populations in Asia.